Vol 68, No 4 (2017)
Original paper
Published online: 2017-05-31

open access

Page views 2025
Article views/downloads 1852
Get Citation

Connect on Social Media

Connect on Social Media

Adipokine profile in patients with anorexia nervosa

Agnieszka Baranowska-Bik1, Bogusława Baranowska2, Lidia Martyńska3, Anna Litwiniuk3, Małgorzata Kalisz3, Jan Kochanowski2, Wojciech Bik4
Pubmed: 28604943
Endokrynol Pol 2017;68(4):422-429.


Introduction: Anorexia nervosa (AN) is an eating disorder characterised with extremely low weight. Adipokines are adipose tissue-derived substances that show a wide spectrum of biological activities. We aimed to assess selected adipokine levels in women with AN before and after nutritional intervention. We also sought to examine whether BMI is the only confounding factor influencing adipokine assessment in AN.

Material and methods: Sixty-five women participated in the study: 20 individuals with AN before any treatment, 18 AN patients after nutritional intervention lasting for at least six months, and 27 women as controls. In all participants blood collection and anthropometric measurements were performed. ELISA was used for evaluation of leptin receptor, adiponectin and its isoforms, and resistin. Leptin was assessed with RIA, and visfatin was measured with EIA assay.

Results: Leptin and free leptin index (FLI) were lowest in treatment–naïve AN women. HMW-adiponectin and visfatin were enhanced in AN. Other adipokine levels showed no significant differences. When two subsets of anorexia nervosa were compared, only leptin, leptin receptor, and FLI were markedly different. When data were adjusted to BMI, leptin and FLI remained significantly different in the pre-treated AN subgroup when compared with the control group.

Conclusions: Our results suggest that leptin is the most important adipokine in AN. It is also important that in our AN population leptin and FLI are the only factors that are influenced not only by the fat content.


  1. Yannakoulia M, Yiannakouris N, Blüher S, et al. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab. 2003; 88(4): 1730–1736.
  2. Kowalska I, Karczewska-Kupczewska M, Strączkowski M. Adipocytokines, gut hormones and growth factors in anorexia nervosa. Clin Chim Acta. 2011; 412(19-20): 1702–1711.
  3. Ziora KT, Oswiecimska JM, Swietochowska E, et al. Assessment of serum levels resistin in girls with anorexia nervosa. Part I. Relationship between resistin and body mass index. Neuro Endocrinol Lett. 2011; 32(5): 691–696.
  4. Zipfel S, Giel KE, Bulik CM, et al. Anorexia nervosa: aetiology, assessment, and treatment. Lancet Psychiatry. 2015; 2(12): 1099–1111.
  5. Peat C, Mitchell JE, Hoek HW, et al. Validity and utility of subtyping anorexia nervosa. Int J Eat Disord. 2009; 42(7): 590–594.
  6. Smink FRE, van Hoeken D, Hoek HW. Epidemiology of eating disorders: incidence, prevalence and mortality rates. Curr Psychiatry Rep. 2012; 14(4): 406–414.
  7. Pike KM, Dunne PE. The rise of eating disorders in Asia: a review. J Eat Disord. 2015; 3: 33.
  8. Arcelus J, Witcomb GL, Mitchell A. Prevalence of eating disorders amongst dancers: a systemic review and meta-analysis. Eur Eat Disord Rev. 2014; 22(2): 92–101.
  9. Brandys MK, de Kovel CGF, Kas MJ, et al. Overview of genetic research in anorexia nervosa: The past, the present and the future. Int J Eat Disord. 2015; 48(7): 814–825.
  10. Misra M, Klibanski A. Endocrine consequences of anorexia nervosa. The Lancet Diabetes & Endocrinology. 2014; 2(7): 581–592.
  11. Misra M, Klibanski A. Neuroendocrine Consequences of Anorexia Nervosa in Adolescents. Endocr Dev. 2009: 197–214.
  12. Warren MP. Endocrine manifestations of eating disorders. J Clin Endocrinol Metab. 2011; 96(2): 333–343.
  13. Baranowska B, Baranowska-Bik A, Bik W, et al. The role of leptin and orexins in the dysfunction of hypothalamo-pituitary-gonadal regulation and in the mechanism of hyperactivity in patients with anorexia nervosa. Neuro Endocrinol Lett. 2008; 29(1): 37–40.
  14. Baranowska B, Wolinska-Witort E, Wasilewska-Dziubinska E, et al. The role of neuropeptides in the disturbed control of appetite and hormone secretion in eating disorders. Neuro Endocrinol Lett. 2003; 24(6): 431–434.
  15. Delporte ML, Brichard SM, Hermans MP, et al. Hyperadiponectinaemia in anorexia nervosa. Clin Endocrinol (Oxf). 2003; 58(1): 22–29.
  16. Dostálová I, Smitka K, Papezová H, et al. Increased insulin sensitivity in patients with anorexia nervosa: the role of adipocytokines. Physiol Res. 2007; 56(5): 587–594.
  17. Misra M, Miller KK, Almazan C, et al. Hormonal and body composition predictors of soluble leptin receptor, leptin, and free leptin index in adolescent girls with anorexia nervosa and controls and relation to insulin sensitivity. J Clin Endocrinol Metab. 2004; 89(7): 3486–3495.
  18. Terra X, Auguet T, Agüera Z, et al. Adipocytokine levels in women with anorexia nervosa. Relationship with weight restoration and disease duration. Int J Eat Disord. 2013; 46(8): 855–861.
  19. Monteleone P, Fabrazzo M, Tortorella A, et al. Opposite modifications in circulating leptin and soluble leptin receptor across the eating disorder spectrum. Mol Psychiatry. 2002; 7(6): 641–646.
  20. Chan JL, Mantzoros CS. Role of leptin in energy-deprivation states: normal human physiology and clinical implications for hypothalamic amenorrhoea and anorexia nervosa. Lancet. 2005; 366(9479): 74–85.
  21. Monteleone P, Maj M. Dysfunctions of leptin, ghrelin, BDNF and endocannabinoids in eating disorders: beyond the homeostatic control of food intake. Psychoneuroendocrinology. 2013; 38(3): 312–330.
  22. Monteleone P, Castaldo E, Maj M. Neuroendocrine dysregulation of food intake in eating disorders. Regul Pept. 2008; 149(1-3): 39–50.
  23. Baskaran C, Eddy KT, Miller KK, et al. Leptin secretory dynamics and associated disordered eating psychopathology across the weight spectrum. Eur J Endocrinol. 2016; 174(4): 503–512.
  24. Kratzsch J, Lammert A, Bottner A, et al. Circulating soluble leptin receptor and free leptin index during childhood, puberty, and adolescence. J Clin Endocrinol Metab. 2002; 87(10): 4587–4594.
  25. Krsek M, Rosická M, Haluzík M, et al. Soluble leptin receptor levels in patients with anorexia nervosa. Endocr Res. 2002; 28(3): 199–205.
  26. Nogueira JP, Maraninchi M, Lorec AM, et al. Specific adipocytokines profiles in patients with hyperactive and/or binge/purge form of anorexia nervosa. Eur J Clin Nutr. 2010; 64(8): 840–844.
  27. Amitani H, Asakawa A, Ogiso K, et al. The role of adiponectin multimers in anorexia nervosa. Nutrition. 2013; 29(1): 203–206.
  28. Iwahashi H, Funahashi T, Kurokawa N, et al. Plasma adiponectin levels in women with anorexia nervosa. Horm Metab Res. 2003; 35(9): 537–540.
  29. Misra M, Miller KK, Cord J, et al. Relationships between serum adipokines, insulin levels, and bone density in girls with anorexia nervosa. J Clin Endocrinol Metab. 2007; 92(6): 2046–2052.
  30. Bosy-Westphal A, Brabant G, Haas V, et al. Determinants of plasma adiponectin levels in patients with anorexia nervosa examined before and after weight gain. Eur J Nutr. 2005; 44(6): 355–359.
  31. Housova J, Anderlova K, Krizová J, et al. Serum adiponectin and resistin concentrations in patients with restrictive and binge/purge form of anorexia nervosa and bulimia nervosa. J Clin Endocrinol Metab. 2005; 90(3): 1366–1370.
  32. Krízová J, Dolinková M, Lacinová Z, et al. Adiponectin and resistin gene polymorphisms in patients with anorexia nervosa and obesity and its influence on metabolic phenotype. Physiol Res. 2008; 57(4): 539–546.
  33. Modan-Moses D, Stein D, Pariente C, et al. Modulation of adiponectin and leptin during refeeding of female anorexia nervosa patients. J Clin Endocrinol Metab. 2007; 92(5): 1843–1847.
  34. Karczewska-Kupczewska M, Straczkowski M, Adamska A, et al. Insulin sensitivity, metabolic flexibility, and serum adiponectin concentration in women with anorexia nervosa. Metabolism. 2010; 59(4): 473–477.
  35. Pannacciulli N, Vettor R, Milan G, et al. Anorexia nervosa is characterized by increased adiponectin plasma levels and reduced nonoxidative glucose metabolism. J Clin Endocrinol Metab. 2003; 88(4): 1748–1752.
  36. Tagami T, Satoh N, Usui T, et al. Adiponectin in anorexia nervosa and bulimia nervosa. J Clin Endocrinol Metab. 2004; 89(4): 1833–1837.
  37. Paniagua JA. Nutrition, insulin resistance and dysfunctional adipose tissue determine the different components of metabolic syndrome. World J Diabetes. 2016; 7(19): 483–514.
  38. Ziora K, Oświęcimska J, Swiętochowska E, et al. Assessment of serum visfatin levels in girls with anorexia nervosa. Clin Endocrinol (Oxf). 2012; 76(4): 514–519.
  39. Dostálová I, Sedlácková D, Papezová H, et al. Serum visfatin levels in patients with anorexia nervosa and bulimia nervosa. Physiol Res. 2009; 58(6): 903–907.
  40. Seidel M, King JA, Ritschel F, et al. Serum visfatin concentration in acutely ill and weight-recovered patients with anorexia nervosa. Psychoneuroendocrinology. 2015; 53: 127–135.
  41. Dostalova I, Kunesova M, Duskova J, et al. Adipose tissue resistin levels in patients with anorexia nervosa. Nutrition. 2006; 22(10): 977–983.
  42. Schorr M, Lawson EA, Dichtel LE, et al. Cortisol Measures Across the Weight Spectrum. J Clin Endocrinol Metab. 2015; 100(9): 3313–3321.